196 related articles for article (PubMed ID: 25618296)
1. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease.
Choudhary D; Hegde P; Voznesensky O; Choudhary S; Kopsiaftis S; Claffey KP; Pilbeam CC; Taylor JA
Urol Oncol; 2015 Sep; 33(9):387.e17-27. PubMed ID: 25618296
[TBL] [Abstract][Full Text] [Related]
2. Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.
Poyet C; Thomas L; Benoit TM; Delmo DA; Luberto L; Banzola I; Günthart MS; Sais G; Eberli D; Sulser T; Provenzano M
Oncotarget; 2017 Mar; 8(13):21871-21883. PubMed ID: 28423532
[TBL] [Abstract][Full Text] [Related]
3. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
[TBL] [Abstract][Full Text] [Related]
5. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
7. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
8. Sialosyl-Le(x) expression defines invasive and metastatic properties of bladder carcinoma.
Numahata K; Satoh M; Handa K; Saito S; Ohyama C; Ito A; Takahashi T; Hoshi S; Orikasa S; Hakomori SI
Cancer; 2002 Feb; 94(3):673-85. PubMed ID: 11857299
[TBL] [Abstract][Full Text] [Related]
9. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
10. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475
[TBL] [Abstract][Full Text] [Related]
11. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma.
Taga M; Hoshino H; Low S; Imamura Y; Ito H; Yokoyama O; Kobayashi M
Urol Oncol; 2015 Nov; 33(11):496.e1-9. PubMed ID: 26137907
[TBL] [Abstract][Full Text] [Related]
12. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
13. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
14. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
[TBL] [Abstract][Full Text] [Related]
15. Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance.
Tang X; Xing J; Li W; Wu Z; Zhang K; Zheng J
J BUON; 2013; 18(1):211-9. PubMed ID: 23613408
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder.
Md Akhir MKA; Hussin H; Veerakumarasivam A; Choy CS; Abdullah MA; Abd Ghani F
Malays J Pathol; 2017 Dec; 39(3):227-234. PubMed ID: 29279584
[TBL] [Abstract][Full Text] [Related]
17. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
18. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
19. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Zhu J; Lu Z; Ke M; Cai X
Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
